Evidence map›Paper›PMID 40952900›Full record

Trial reportClinical and translational science2025

Safety, Pharmacokinetics, and Pharmacodynamics of BI 1595043, a Selective Vanin Inhibitor, in Phase 1 Clinical Trials Involving Healthy Volunteers.

Anjli Kukreja, Sascha Keller, Yury Shatillo, Andras Bauer, Ashish Sharma, Stephan Wojciekowski, Sudha Visvanathan, Stella Aslanyan

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Synthesis of Potent Vanin-1 Inhibitors Labelled With Carbon-14 and Deuterium.Journal of labelled compounds & radiopharmaceuticals · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anjli KukrejaBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Sascha KellerBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Yury ShatilloBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Andras BauerBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Ashish SharmaBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Stephan WojciekowskiBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Sudha VisvanathanBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
Stella AslanyanVeloxis Pharmaceuticals, Inc., Cary, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BI 1595043 is an oral vanin-1 and vanin-2 inhibitor, which demonstrated promising effects on epithelial cell protection and reduction of inflammatory mediators in preclinical studies, as well as an acceptable safety profile in a previous single-rising-dose trial. Here, we report the results of a double-blind, randomized, placebo-controlled, multiple rising dose study, which investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1595043 in healthy male volunteers following oral administration of single and multiple rising doses over 18 days in total. Thirty subjects were treated (18-50 years of age; body mass index: 18.5-29.9 kg/m

Indexed as

AmidohydrolasesAdministration, OralAdolescentAdultDose-Response Relationship, DrugDouble-Blind MethodGPI-Linked ProteinsHealthy VolunteersHumansMaleMiddle AgedYoung AdultAmidohydrolasesGPI-Linked ProteinspantetheinaseBI 1595043clinical trialCrohn's diseasecysteaminehealthy volunteersinflammationinflammatory bowel diseaseoxidation–reductionpantetheinasevanin inhibition

Identifiers

PMID40952900
PMCPMC12435493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.